Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
Rolf Hilgenfeld, Gerhard Seipke, Harald Berchtold, et al.
Drugs (2014) Vol. 74, Iss. 8, pp. 911-927
Open Access | Times Cited: 103

Showing 26-50 of 103 citing articles:

Diselenide-bond replacement of the external disulfide bond of insulin increases its oligomerization leading to sustained activity
Kenta Arai, Masaki Okumura, Young‐Ho Lee, et al.
Communications Chemistry (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 7
Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
Sergei Pechenov, Himanshu Bhattacharjee, Dan Yin, et al.
Advanced Drug Delivery Reviews (2017) Vol. 112, pp. 106-122
Closed Access | Times Cited: 20
Comparative study on the deamidation of three recombinant human insulins using capillary electrophoresis
Melinda Andrási, Gayatri Vishwakarma, Ruben Szabo, et al.
Journal of Chromatography A (2023) Vol. 1706, pp. 464286-464286
Open Access | Times Cited: 6
Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
Robyn K. Pollom, Liza L. Ilag, Lyndon B. Lacaya, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 1, pp. 189-203
Open Access | Times Cited: 16
The quaternary structure of insulin glargine and glulisine under formulation conditions
N. Nagel, Melissa A. Graewert, Mimi Gao, et al.
Biophysical Chemistry (2019) Vol. 253, pp. 106226-106226
Closed Access | Times Cited: 16
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin
Patrick F. Frias, Juan P. Frías
Current Diabetes Reports (2017) Vol. 17, Iss. 10
Closed Access | Times Cited: 16
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Riccardo Candido, Kathleen Wyne, Ester Romoli
Diabetes Therapy (2018) Vol. 9, Iss. 3, pp. 927-949
Open Access | Times Cited: 16
Molecular Details of a Salt Bridge and Its Role in Insulin Fibrillation by NMR and Raman Spectroscopic Analysis
Bhisma N. Ratha, Rajiv K. Kar, Zuzana Bednarikova, et al.
The Journal of Physical Chemistry B (2020) Vol. 124, Iss. 7, pp. 1125-1136
Closed Access | Times Cited: 13
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
David R. Owens, L. Monnier, Antonio Ceriello, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S1, pp. 27-42
Open Access | Times Cited: 12
Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems
Martin K. Kuhlmann, Andrea E. Schmidt
Biosimilars (2014), pp. 45-45
Open Access | Times Cited: 13
Buried Kex2 Sites in Glargine Precursor Aggregates Prevent Its Intracellular Processing in Pichia pastoris Muts Strains and the Effect of Methanol-Feeding Strategy and Induction Temperature on Glargine Precursor Production Parameters
Abel Caballero-Pérez, Jose Marı́a Viader-Salvadó, Ana Lucía Herrera-Estala, et al.
Applied Biochemistry and Biotechnology (2021) Vol. 193, Iss. 9, pp. 2806-2829
Closed Access | Times Cited: 11
Overcoming Cellular and Systemic Barriers to Design the Next Wave of Peptide Therapeutics
Jerome Hochman, Tomi K. Sawyer, Ruchia Duggal
Methods in pharmacology and toxicology (2021), pp. 201-227
Closed Access | Times Cited: 11
Semisynthesis of A6–A11 lactam insulin
Rong Xu, Edwina Jap, Ben Gubbins, et al.
Journal of Peptide Science (2023)
Open Access | Times Cited: 4
Enhancing inter-subject reproducibility in insulin bioavailability measurements through real-time calibration
Pasquale Arpaïa, Fortuna Galdieri, Francesca Mancino, et al.
Measurement (2024) Vol. 231, pp. 114603-114603
Open Access | Times Cited: 1
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol
Peter Novodvorský, Lenka Thieme, Ivana Laňková, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 6, pp. 1461-1471
Open Access | Times Cited: 1
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Sheridan M. Hoy
BioDrugs (2020) Vol. 34, Iss. 2, pp. 245-251
Open Access | Times Cited: 10
Insulin Release from NPH Insulin-Loaded Pluronic® F127 Hydrogel in the Presence of Simulated Tissue Enzyme Activity
Muhammad H. Sultan, Wael A. Mahdi, Young Min Kwon
Processes (2020) Vol. 8, Iss. 10, pp. 1320-1320
Open Access | Times Cited: 10
Recent advancements in oral delivery of insulin: from challenges to solutions
Raje Chouhan, Shilpi Goswami, A. K. Bajpai
Elsevier eBooks (2017), pp. 435-465
Closed Access | Times Cited: 9
Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins
Jing Xing, Yan Hou, William Hallett, et al.
Advances in experimental medicine and biology (2019), pp. 115-129
Closed Access | Times Cited: 9
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Peter Novodvorský, Martin Haluzı́k
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 3, pp. 349-361
Closed Access | Times Cited: 8
Biosimilar of analogue of insulin glargin: proven safety, effectiveness, interchangeability
С. В. Булгакова, E. N. Saverskaya, Л. А. Шаронова, et al.
Meditsinskiy sovet = Medical Council (2023), Iss. 23, pp. 207-214
Open Access | Times Cited: 3
Se-Glargine II. Native Function of a Basal Insulin Analog Stabilized by an Internal Diselenide Bridge
Yen‐Shan Chen, Balamurugan Dhayalan, Yanwu Yang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Cell Adhesive Character of Phenylboronic Acid-Modified Insulin and Its Potential as Long-Acting Insulin
Yui Ohno, Momoko Kawakami, Tomohiro Seki, et al.
Pharmaceuticals (2019) Vol. 12, Iss. 3, pp. 121-121
Open Access | Times Cited: 8
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR ® /ABASAGLAR ® ) approved in the European Union
Richard A. Byrd, Rebecca A. Owens, Jamie L. Blackbourne, et al.
Regulatory Toxicology and Pharmacology (2017) Vol. 88, pp. 56-65
Closed Access | Times Cited: 7
Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial
Anika Bilal, Richard E. Pratley
Current Diabetes Reports (2018) Vol. 18, Iss. 11
Closed Access | Times Cited: 7

Scroll to top